USPTO cancelled trademark registration TM79222116 for "Trimodulin" effective April 2, 2026. The trademark covered pharmaceutical immunoglobulin preparations for treatment of immunological disorders and bacterial infections, specifically severe community-acquired pneumonia. The original application was filed October 19, 2017. Trademark cancellations are routine administrative proceedings that terminate the legal protection of a registered mark.

This cancellation does not impose compliance obligations on other market participants. Pharmaceutical companies and drug manufacturers should verify their trademark portfolios to ensure active registrations remain in good standing. No action is required regarding this specific cancellation unless the party held related registration interests.